These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 29045530)

  • 1. Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA analysis in metastatic breast cancer.
    Fribbens C; Garcia Murillas I; Beaney M; Hrebien S; O'Leary B; Kilburn L; Howarth K; Epstein M; Green E; Rosenfeld N; Ring A; Johnston S; Turner N
    Ann Oncol; 2018 Jan; 29(1):145-153. PubMed ID: 29045530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of early progression according to circulating ESR1 mutation, CA-15.3 and cfDNA increases under first-line anti-aromatase treatment in metastatic breast cancer.
    Clatot F; Perdrix A; Beaussire L; Lequesne J; Lévy C; Emile G; Bubenheim M; Lacaille S; Calbrix C; Augusto L; Guillemet C; Alexandru C; Fontanilles M; Sefrioui D; Burel L; Guénot S; Richard D; Sarafan-Vasseur N; Di Fiore F
    Breast Cancer Res; 2020 May; 22(1):56. PubMed ID: 32466779
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Turner NC; Swift C; Kilburn L; Fribbens C; Beaney M; Garcia-Murillas I; Budzar AU; Robertson JFR; Gradishar W; Piccart M; Schiavon G; Bliss JM; Dowsett M; Johnston SRD; Chia SK
    Clin Cancer Res; 2020 Oct; 26(19):5172-5177. PubMed ID: 32546646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kinetics, prognostic and predictive values of ESR1 circulating mutations in metastatic breast cancer patients progressing on aromatase inhibitor.
    Clatot F; Perdrix A; Augusto L; Beaussire L; Delacour J; Calbrix C; Sefrioui D; Viailly PJ; Bubenheim M; Moldovan C; Alexandru C; Tennevet I; Rigal O; Guillemet C; Leheurteur M; Gouérant S; Petrau C; Théry JC; Picquenot JM; Veyret C; Frébourg T; Jardin F; Sarafan-Vasseur N; Di Fiore F
    Oncotarget; 2016 Nov; 7(46):74448-74459. PubMed ID: 27801670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating ESR1 mutations at the end of aromatase inhibitor adjuvant treatment and after relapse in breast cancer patients.
    Allouchery V; Beaussire L; Perdrix A; Sefrioui D; Augusto L; Guillemet C; Sarafan-Vasseur N; Di Fiore F; Clatot F
    Breast Cancer Res; 2018 May; 20(1):40. PubMed ID: 29769099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.
    Fribbens C; O'Leary B; Kilburn L; Hrebien S; Garcia-Murillas I; Beaney M; Cristofanilli M; Andre F; Loi S; Loibl S; Jiang J; Bartlett CH; Koehler M; Dowsett M; Bliss JM; Johnston SR; Turner NC
    J Clin Oncol; 2016 Sep; 34(25):2961-8. PubMed ID: 27269946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating Tumor DNA Profiling From Breast Cancer Screening Through to Metastatic Disease.
    Page K; Martinson LJ; Fernandez-Garcia D; Hills A; Gleason KLT; Gray MC; Rushton AJ; Nteliopoulos G; Hastings RK; Goddard K; Ions C; Parmar V; Primrose L; Openshaw MR; Guttery DS; Palmieri C; Ali S; Stebbing J; Coombes RC; Shaw JA
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34849446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.
    Najim O; Seghers S; Sergoynne L; Van Gaver H; Papadimitriou K; Wouters K; Trinh XB; Huizing MT; Tjalma W
    Biochim Biophys Acta Rev Cancer; 2019 Dec; 1872(2):188315. PubMed ID: 31647985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis.
    Zundelevich A; Dadiani M; Kahana-Edwin S; Itay A; Sella T; Gadot M; Cesarkas K; Farage-Barhom S; Saar EG; Eyal E; Kol N; Pavlovski A; Balint-Lahat N; Dick-Necula D; Barshack I; Kaufman B; Gal-Yam EN
    Breast Cancer Res; 2020 Feb; 22(1):16. PubMed ID: 32014063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short report: Monitoring ESR1 mutations by circulating tumor DNA in aromatase inhibitor resistant metastatic breast cancer.
    Sefrioui D; Perdrix A; Sarafan-Vasseur N; Dolfus C; Dujon A; Picquenot JM; Delacour J; Cornic M; Bohers E; Leheurteur M; Rigal O; Tennevet I; Thery JC; Alexandru C; Guillemet C; Moldovan C; Veyret C; Frebourg T; Di Fiore F; Clatot F
    Int J Cancer; 2015 Nov; 137(10):2513-9. PubMed ID: 25994408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer.
    Schiavon G; Hrebien S; Garcia-Murillas I; Cutts RJ; Pearson A; Tarazona N; Fenwick K; Kozarewa I; Lopez-Knowles E; Ribas R; Nerurkar A; Osin P; Chandarlapaty S; Martin LA; Dowsett M; Smith IE; Turner NC
    Sci Transl Med; 2015 Nov; 7(313):313ra182. PubMed ID: 26560360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prevalence of estrogen receptor-1 mutation in advanced breast cancer: The estrogen receptor one study (EROS1).
    Najim O; Huizing M; Papadimitriou K; Trinh XB; Pauwels P; Goethals S; Zwaenepoel K; Peterson K; Weyler J; Altintas S; van Dam P; Tjalma W
    Cancer Treat Res Commun; 2019; 19():100123. PubMed ID: 30826563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of endocrine resistance using ESR1 genotyping of circulating tumor cells and plasma DNA.
    Sundaresan TK; Dubash TD; Zheng Z; Bardia A; Wittner BS; Aceto N; Silva EJ; Fox DB; Liebers M; Kapur R; Iafrate J; Toner M; Maheswaran S; Haber DA
    Breast Cancer Res Treat; 2021 Jul; 188(1):43-52. PubMed ID: 34101078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating tumour DNA in metastatic breast cancer to guide clinical trial enrolment and precision oncology: A cohort study.
    Zivanovic Bujak A; Weng CF; Silva MJ; Yeung M; Lo L; Ftouni S; Litchfield C; Ko YA; Kuykhoven K; Van Geelen C; Chandrashekar S; Dawson MA; Loi S; Wong SQ; Dawson SJ
    PLoS Med; 2020 Oct; 17(10):e1003363. PubMed ID: 33001984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical significance of monitoring ESR1 mutations in circulating cell-free DNA in estrogen receptor positive breast cancer patients.
    Takeshita T; Yamamoto Y; Yamamoto-Ibusuki M; Inao T; Sueta A; Fujiwara S; Omoto Y; Iwase H
    Oncotarget; 2016 May; 7(22):32504-18. PubMed ID: 27102299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial.
    Turner NC; Kingston B; Kilburn LS; Kernaghan S; Wardley AM; Macpherson IR; Baird RD; Roylance R; Stephens P; Oikonomidou O; Braybrooke JP; Tuthill M; Abraham J; Winter MC; Bye H; Hubank M; Gevensleben H; Cutts R; Snowdon C; Rea D; Cameron D; Shaaban A; Randle K; Martin S; Wilkinson K; Moretti L; Bliss JM; Ring A
    Lancet Oncol; 2020 Oct; 21(10):1296-1308. PubMed ID: 32919527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1.
    Berger F; Marce M; Delaloge S; Hardy-Bessard AC; Bachelot T; Bièche I; Pradines A; De La Motte Rouge T; Canon JL; André F; Arnould L; Clatot F; Lemonnier J; Marques S; Bidard FC;
    BMJ Open; 2022 Mar; 12(3):e055821. PubMed ID: 35241469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metastatic Breast Cancer With ESR1 Mutation: Clinical Management Considerations From the Molecular and Precision Medicine (MAP) Tumor Board at Massachusetts General Hospital.
    Bardia A; Iafrate JA; Sundaresan T; Younger J; Nardi V
    Oncologist; 2016 Sep; 21(9):1035-40. PubMed ID: 27551012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular characterisation of aromatase inhibitor-resistant advanced breast cancer: the phenotypic effect of ESR1 mutations.
    Lopez-Knowles E; Pearson A; Schuster G; Gellert P; Ribas R; Yeo B; Cutts R; Buus R; Garcia-Murillas I; Haynes B; Martin LA; Smith I; Turner N; Dowsett M
    Br J Cancer; 2019 Jan; 120(2):247-255. PubMed ID: 30563991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer.
    Chung JH; Pavlick D; Hartmaier R; Schrock AB; Young L; Forcier B; Ye P; Levin MK; Goldberg M; Burris H; Gay LM; Hoffman AD; Stephens PJ; Frampton GM; Lipson DM; Nguyen DM; Ganesan S; Park BH; Vahdat LT; Leyland-Jones B; Mughal TI; Pusztai L; O'Shaughnessy J; Miller VA; Ross JS; Ali SM
    Ann Oncol; 2017 Nov; 28(11):2866-2873. PubMed ID: 28945887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.